Clinical Trial Detail

NCT ID NCT02872714
Title A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Incyte Corporation
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

transitional cell carcinoma

Therapies

Pemigatinib

Age Groups: adult senior

Additional content available in CKB BOOST